• 首页
  • 关于期刊
    期刊简介
    编委会
    青年编委会
    合作单位
    《药学研究》编辑部
  • 投稿指南
  • 制度与声明
    出版伦理规范
    学术不端声明
    开放获取(OA)声明
    AIGC工具使用声明
  • 期刊订阅
  • 下载中心
  • English
引用本文:李新新,王燕芹,邢潇匀,潘磊,马蕾.Ixekizumab治疗中重度斑块型银屑病疗效和安全性系统评价[J].药学研究,2020,39(4):236-243[点击复制]
【打印本页】      【下载PDF全文】   【查看/发表评论】  【下载PDF阅读器】  【关闭】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 2753次   下载 3683次 本文二维码信息
码上扫一扫!
Ixekizumab治疗中重度斑块型银屑病疗效和安全性系统评价
李新新1,王燕芹1,邢潇匀1,潘磊2,马蕾1
字体:加大+|默认|缩小-
(1.滨州医学院附属医院皮肤科,山东 滨州 256603;2.滨州医学院附属医院呼吸科,山东 滨州 256603)
摘要:
目的 系统评价Ixekizumab治疗中重度斑块型银屑病的疗效和安全性。方法 计算机检索PubMed、ClinicalTrials、Web of Science、Cochrane图书馆、EMBASE、Ovid、Google Scholar、WHO国际临床试验注册平台、中国临床试验注册中心等数据库有关Ixekizumab治疗中重度斑块型银屑病的随机对照临床试验(RCT),按照纳入与排除标准筛选文献、评价质量、提取资料,应用 RevMan5.3软件进行系统评价,两个以上研究进行meta分析。结果 共纳入4项RCT研究,包括3 866例患者。总的结果显示:Ixekizumab(160 mg起始量,随后80 mg/2周或80 mg/4周)治疗12周,获银屑病皮损面积和严重程度指数下降 75%、90%、100%(PASI 75、PASI 90、PASI 100)以及达到医师静态总体评价为清除或几乎清除(sPGA0或sPGA0/1)的患者比率均显著高于安慰剂组和依那西普组(50 mg/2周);亚组分析提示Ixekizumab 80mg/2周的PASI 75、PASI 90、PASI 100、sPGA0、sPGA0/1的患者比率明显高于80mg/4周亚组;Ixekizumab治疗60周,获PASI 90 和PASI 100的患者比率较治疗12周进一步提高。安全性方面,Ixekizumab组治疗12周,感染和注射部位反应发生率较安慰剂组高,但总的不良反应和严重不良反应等不良事件发生率差异无统计学意义;80 mg/2周治疗组发生注射部位反应的患者比率明显高于80 mg/4周,但两组间其他不良反应发生情况比较差异均无统计学意义。结论 现有证据表明,Ixekizumab治疗中重度斑块型银屑病具有良好的疗效和短期安全性,长期用药安全性有待进一步评估。
关键词:  Ixekizumab  斑块型银屑病  随机对照试验  系统评价
DOI:10.13506/j.cnki.jpr.2020.04.011
基金项目:国家自然科学基金(No.81803145)
Efficacy and safety of Ixekizumab for Moderate to Severe Plaque Psoriasis: A Systematic Review
LI Xinxin1,WANG Yanqin1,XING Xiaoyun1,PAN Lei2,MA Lei1
(1.Department of Dermatology, Binzhou Medical University Hospital, Binzhou 256603,China;2.Department of Respiratory,Binzhou Medical University Hospital, Binzhou 256603, China)
Abstract:
Objective To evaluate the efficacy and safety of Ixekizumab for the treatment of plaque psoriasis by systematic review.Methods PubMed, Clinical Trials, Web of Science, Cochrane Library, EMBASE, Ovid, Google Scholar, WHO ICTRP, Chinese Clinical Trial Registry were searched to collect randomized controlled trials (RCTs) about the efficacy and safety of Ixekizumab for the treatment of plaque psoriasis. According to the predefined inclusion and exclusion criteria, we screened the retrieved studies, evaluated the quality of included studies, and performed systematic review by using Cochrane Collaboration’s RevMan 5.3 software, and more than two studies were conduct meta-analyses.Results Four RCTs involving 3 866 patients with moderate to severe plaque psoriasis were included and assessed. The proportion of patients reaching up to 75%, 90% and 100% psoriasis area and severity index (PASI 75, PASI 90 and PASI 100)and Static Physician’s Global Assessment (sPGA) of 0 and/or 0/1 were therapeutic Indicators. At week 12, response rates for PASI 75, PASI 90, PASI 100, sPGA 0 and sPGA 0/1 were significantly higher for Ixekizumab-treated group (160 mg starting dose, then 80mg every 2 or 4 weeks) than for placebo group and etanercept-treated group (50mg every 2 weeks). Further comparison between subgroups of Ixekizumab treatment showed that response rates for PASI 75, PASI 90, PASI 100, sPGA 0 and sPGA 0/1 were obviously higher for 80 mg every 2 weeks subgroup than 80 mg every 4 weeks subgroup. Moreover, response rates for PASI 90 and PASI 100 were distinctly increased for Ixekizumab treatment at week 60 compared with Ixekizumab treatment at week 12. In terms of safety, at week 12, the incidence of infection and injection site reaction in Ixekizumab-treated group was higher than those in placebo group, while the two groups did not differ with regard to overall incidences of any adverse events and serious adverse events. The incidence of injection site reaction in 80mg every 2 weeks group was higher than those in 80mg every 4 weeks group, while the two groups did not differ with other adverse events.Conclusion The present evidence indicates that Ixekizumab is efficient and safe in short-term for the treatment of moderate-to-severe plaque psoriasis, and its long-term safety is deserved to explore.
Key words:  Ixekizumab  Plaque psoriasis  Randomized controlled trials  Systematic review
今日访问量:2339    总访问量:55338711
网站版权:《药学研究》编辑部     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
主办:山东省食品药品检验研究院、山东省药学会 地址:山东省济南市高新区新泺大街2749号 邮政编码:250101
电话:0531-81216586 电子邮箱:yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
技术支持:北京勤云科技有限公司